Short answer
Arcturus Therapeutics Holdings Inc. (ARCT) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $3M (down 89.5% year over year) with net income of −$24M.
Q2 2026 key financials · XBRL
- Revenue
- $3M
- −89.5% YoY · +43.6% QoQ
- Net income
- −$24M
- −159.1% YoY · +11.8% QoQ
- Operating margin
- -863.3%
- EPS (diluted)
- −$0.84
- −147.1% YoY · +11.6% QoQ
Source: XBRL data from the Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2026 10-Q on SEC EDGAR. USD.
Arcturus Therapeutics Holdings Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.0M, down 90% YoY from $28.3M, driven by lower CSL collaboration revenue
- Operating expenses $28.5M, down 29% YoY from $39.9M
- LUNAR-CF R&D $2.6M, down 44% YoY; LUNAR-OTC $1.9M, down 36%
- Cash $191.5M at June 30; six-month operating cash outflow $39.4M vs $40.9M
- Outlook: losses expected to continue; cash sufficient through at least next twelve months; additional capital anticipated
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arcturus Therapeutics Holdings Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.